Goldman Sachs Raises NewAmsterdam Pharma PT to $37, Maintains Neutral Rating

martes, 2 de diciembre de 2025, 1:16 pm ET1 min de lectura
NAMS--

Goldman Sachs Raises NewAmsterdam Pharma PT to $37, Maintains Neutral Rating

Goldman Sachs Raises NewAmsterdam Pharma PT to $37, Maintains Neutral Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios